Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4476455
Max Phase: Preclinical
Molecular Formula: C29H29F2N5O5
Molecular Weight: 565.58
Molecule Type: Unknown
Associated Items:
ID: ALA4476455
Max Phase: Preclinical
Molecular Formula: C29H29F2N5O5
Molecular Weight: 565.58
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=C1C(=O)O[C@H]2[C@H]1CC/C(Cn1cc(Cn3cc(F)c(=O)n(Cc4ccc(F)cc4)c3=O)nn1)=C\CC[C@@]1(C)O[C@@H]21
Standard InChI: InChI=1S/C29H29F2N5O5/c1-17-22-10-7-18(4-3-11-29(2)25(41-29)24(22)40-27(17)38)12-35-15-21(32-33-35)14-34-16-23(31)26(37)36(28(34)39)13-19-5-8-20(30)9-6-19/h4-6,8-9,15-16,22,24-25H,1,3,7,10-14H2,2H3/b18-4+/t22-,24-,25-,29+/m0/s1
Standard InChI Key: UDGKPJAUWWXSJE-LUEFZTOZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 565.58 | Molecular Weight (Monoisotopic): 565.2137 | AlogP: 2.73 | #Rotatable Bonds: 6 |
Polar Surface Area: 113.54 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 0.14 | CX LogP: 3.82 | CX LogD: 3.82 |
Aromatic Rings: 3 | Heavy Atoms: 41 | QED Weighted: 0.20 | Np Likeness Score: 0.42 |
1. Ding Y, Li S, Ge W, Liu Z, Zhang X, Wang M, Chen T, Chen Y, Zhang Q.. (2019) Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma., 183 [PMID:31553932] [10.1016/j.ejmech.2019.111706] |
Source(1):